Boehringer Ingelheim
For Healthcare Professionals
jardiance-quiz-logo.png

SELECTED EVIDENCE FROM T2D CVOTS FOR YOUR PATIENTS WITH T2D AND CV RISK*

Daily oral Empagliflozin (JARDIANCE®) provides the broadest cardio-renal benefits1

image (5)
image (5)
profile-box
Patient Profile

  • 52-year-old woman with T2D for 8 years

  • Her HbA1c is 8.5%

  • Overweight

  • Has CAD

  • Currently on metformin, DPP-4i, aspirin

Click to see more

*As mandated by FDA Guidance to industry 2008. Only marketed products have been included in the selection.

†Reductions in HbA1c and body weight.1

‡MACE defined as composite endpoint of CV death, non-fatal MI, or non-fatal stroke. Empagliflozin (JARDIANCE®) reduced the relative risk of CV events by 14% (HR=0.86; 95.02% CI: 0.74, 0.99; p=0.04). CV death was significantly reduced by 38% with no significant difference in non-fatal MI or non-fatal stroke.1,3

§In adult patients with insufficiently controlled T2D and CAD, PAD, or a history of MI or stroke.1,3

llHHF was a secondary CV outcome. An assessment of renal outcomes, incident or worsening nephropathy, was a prespecified component of the secondary microvascular outcome.1,3,4

Reduction in macroalbuminuria seen with semaglutide, dulaglutide, and exenatide weekly injections.7,10

CAD=coronary artery disease; CI=confidence interval; CV=cardiovascular; CVOT=Cardiovascular Outcome Trial; eGFR=estimated glomerular filtration rate; FDA=Food and Drug Administration; GLP-1 RA=glucagon-like peptide-1 receptor agonist; HHF=hospitalisation for heart failure; HR=hazard ratio; MACE=major adverse cardiovascular events; MDI=multiple daily injections; MI=myocardial infarction; PAD=peripheral artery disease; T2D=type 2 diabetes.

  1. Empagliflozin (JARDIANCE®) Prescribing Information 17 March 2022.

  2. Fitchett D, Inzucchi SE, Cannon CP, et al. Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation. 2019;139(11):1384-1395.

  3. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.

  4. Wanner C, Inzucchi SE, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.

  5. Savarese G, Sattar N, Januzzi J, et al. Empagliflozin is associated with a lower risk of post-acute heart failure, rehospitalization and mortality. Circulation. 2019;139(11):1458-1460.

  6. TRULICITY Singapore Prescribing Information, October 2019.

  7. OZEMPIC Singapore Prescribing Information, October 2020.

  8. Holman RR, Bethel MA, Mentz RJ, et al; EXSCEL Study Group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228-1239.

  9. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130.

  10. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131-138.

  11. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. (SUSTAIN-6 results and the publication’s Supplementary Appendix.)

  12. Mann JFE, Hansen T, Idorn T, et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials. Lancet Diabetes Endocrinol. 2020;8(11):880-893.

  13. VICTOZA Singapore Prescribing Information, June 2020.

  14. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.

  15. Mann JFE, Ørsted DD, Brown Frandsen K, et al; LEADER Steering Committee and Investigators. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839-848.